Clinical Trials for ADC Therapeutics

Explore 13 clinical trials worldwide

Showing 1-13 of 13 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: ADC Therapeutics

Clinical Trials (13)

NCT06919939
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
PHASE2Not yet recruiting
26 participants
Started: Dec 1, 2025 · Completed: Dec 1, 2030
2 conditions3 sponsors1 location
NCT06788964
Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma
PHASE2Recruiting
29 participants
Started: Jul 1, 2025 · Completed: Mar 31, 2030
1 condition2 sponsors1 location
NCT06607549
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas (SOLAR)
PHASE1Recruiting
12 participants
Started: Mar 6, 2025 · Completed: Nov 30, 2030
1 condition2 sponsors1 location
NCT05991388
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
PHASE2/PHASE3Recruiting
210 participants
Started: May 2, 2024 · Completed: May 1, 2033
1 condition5 sponsors3 locations
NCT05971251
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
PHASE1Active, not recruiting
24 participants
Started: Dec 18, 2023 · Completed: Dec 31, 2028
1 condition2 sponsors1 location
NCT05660395
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
PHASE1Recruiting
56 participants
Started: Aug 28, 2023 · Completed: Apr 5, 2027
2 conditions1 sponsor14 locations
NCT05600686
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
PHASE2Recruiting
24 participants
Started: May 24, 2023 · Completed: Feb 1, 2028
4 conditions3 sponsors1 location
NCT05296070
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
PHASE2Recruiting
50 participants
Started: Jun 21, 2022 · Completed: Jun 30, 2029
1 condition2 sponsors4 locations
NCT04970901
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
PHASE1Recruiting
200 participants
Started: Jun 17, 2022 · Completed: Oct 29, 2027
3 conditions1 sponsor42 locations
NCT05190705
Loncastuximab Tesirine in WM
PHASE2Recruiting
36 participants
Started: Feb 17, 2022 · Completed: Aug 1, 2028
1 condition2 sponsors4 locations
NCT04998669
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
PHASE2Recruiting
100 participants
Started: Feb 11, 2022 · Completed: Aug 1, 2030
1 condition2 sponsors5 locations
NCT04384484
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
PHASE3Active, not recruiting
440 participants
Started: Sep 16, 2020 · Completed: Jun 30, 2028
2 conditions1 sponsor144 locations
NCT03698552
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
PHASE1/PHASE2Recruiting
57 participants
Started: Aug 24, 2018 · Completed: Dec 31, 2025
5 conditions3 sponsors2 locations